Global Asthma Therapeutics Market 2017 Industry Trends, Growth Rate With CAGR Analysis 2021

Asthma Therapeutics Market

Asthma Therapeutics Market

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Browse Complete Report With TOC @ http://www.marketresearchstore.com/report/asthma-therapeutics-in-asia-pacific-markets-to-2021-52511

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

What are the competitive advantages of the existing novel drugs?
With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

Which classes of novel drugs are most prominent within the pipeline?
Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?
Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

How do failure rates vary by product stage of development, molecule type, and mechanism of action?
How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

Which markets make the most significant contribution to the current market size?
What are the epidemiology trends in these markets?
Will new market entrants lead to substantial changes in annual therapy costs?
How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

Will affordability threaten the commercial success of existing drugs as well as newer biologics?
Which of the assessed countries have affordability concerns?

To Get Sample Copy of Report visit @ http://www.marketresearchstore.com/report/asthma-therapeutics-in-asia-pacific-markets-to-2021-52511#RequestSample

Leave a Reply

Your email address will not be published. Required fields are marked *